Abstract
Diabetes is a primary factor that is accountable for health problems and results in millions of deaths. 4 million deaths approximately occurred due to diabetes every year and about 170 million people are suffering universally. For diabetes, no treatment is present that promises to cure this condition. Only blood glucose monitoring is recommended for diabetics. Regular and close monitoring of glucose levels can help to avoid further serious problems. Determining the level of glucose in the blood is an important requirement. This is done by monitoring the levels of glycated hemoglobin (HbA1c), which is a biomarker for glucose. But HbA1c monitoring is unreliable in the presence of certain medical conditions. In such cases another biomarker glycated albumin (GA) is used for glucose monitoring as it remains unaffected by such conditions. As a result, a bimetallic nanomaterial-based sensitive platform was created. This research focuses on the development of a biosensor that utilizes micro-screen printed electrodes (μSPE). The platform was designed to measure the level of GA and demonstrated the synergistic effects of bi-metallic gold-platinum (Au-Pt) nanomaterial. Additionally, the electrochemical response of mono-metallic and bi-metallic nanoparticles was investigated in order to detect glycated albumin, a diabetes biomarker. The biosensor constructed using bimetallic nanoparticles exhibits a broad range of concentrations, lower limit of detection, heightened sensitivity, and selectivity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.